290 related articles for article (PubMed ID: 16325366)
1. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
Galetta F; Franzoni F; Cervetti G; Cecconi N; Carpi A; Petrini M; Santoro G
Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
[TBL] [Abstract][Full Text] [Related]
2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
3. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma.
Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Nousiainen T; Hartikainen J
Clin Physiol Funct Imaging; 2010 May; 30(3):175-80. PubMed ID: 20132128
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Galetta F; Franzoni F; Cervetti G; Regoli F; Fallahi P; Tocchini L; Carpi A; Antonelli A; Petrini M; Santoro G
Biomed Pharmacother; 2010 Apr; 64(4):259-63. PubMed ID: 19932589
[TBL] [Abstract][Full Text] [Related]
5. Effect of nebivolol on QT dispersion in hypertensive patients with left ventricular hypertrophy.
Galetta F; Franzoni F; Magagna A; Femia FR; Pentimone F; Santoro G; Carpi A
Biomed Pharmacother; 2005; 59(1-2):15-9. PubMed ID: 15740930
[TBL] [Abstract][Full Text] [Related]
6. [QT interval dispersion in hypertensive diabetics and in patients with hypertension with chronic heart failure without diabetes].
Radman A; Murín J; Bulas J; Reptová A; Ravingerová T; Mikes P; Kozliková K; Ghanem W; Jaber J; Baqi L
Vnitr Lek; 2003 Oct; 49(10):802-7. PubMed ID: 14682153
[TBL] [Abstract][Full Text] [Related]
7. QT dispersion and early arrhythmic risk during acute myocardial infarction.
Ciolli A; Di Lorenzo M; Bevilacqua U; Lo Sardo G; Tripi M; Fidati R; Palamara A
G Ital Cardiol; 1999 Dec; 29(12):1438-44. PubMed ID: 10687106
[TBL] [Abstract][Full Text] [Related]
8. Sevoflurane causes greater QTc interval prolongation in elderly patients than in younger patients.
Nakao S; Hatano K; Sumi C; Masuzawa M; Sakamoto S; Ikeda S; Shingu K
Anesth Analg; 2010 Mar; 110(3):775-9. PubMed ID: 20185656
[TBL] [Abstract][Full Text] [Related]
9. Effect of obesity on P-wave dispersion and QT dispersion in women.
Seyfeli E; Duru M; Kuvandik G; Kaya H; Yalcin F
Int J Obes (Lond); 2006 Jun; 30(6):957-61. PubMed ID: 16432544
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
11. Improvement of maximum corrected QT and corrected QT dispersion in electrocardiography after kidney transplantation.
Monfared A; Ghods AJ
Iran J Kidney Dis; 2008 Apr; 2(2):95-8. PubMed ID: 19377216
[TBL] [Abstract][Full Text] [Related]
12. QT interval and QT dispersion in systemic sclerosis (scleroderma).
Sgreccia A; Morelli S; Ferrante L; Perrone C; De Marzio P; De Vincentiis G; Scopinaro F
J Intern Med; 1998 Feb; 243(2):127-32. PubMed ID: 9566641
[TBL] [Abstract][Full Text] [Related]
13. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients.
Busti AJ; Tsikouris JP; Peeters MJ; Das SR; Canham RM; Abdullah SM; Margolis DM
HIV Med; 2006 Jul; 7(5):317-22. PubMed ID: 16945077
[TBL] [Abstract][Full Text] [Related]
14. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
15. [Risk of arrhythmias in hemodialysis patients vs healthy people].
Milone F; Urso S; Garozzo M; Memeo AM; Volpe G; Battaglia G
G Ital Nefrol; 2004; 21 Suppl 30():S241-6. PubMed ID: 15750993
[TBL] [Abstract][Full Text] [Related]
16. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
[TBL] [Abstract][Full Text] [Related]
17. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
Wang P; Zhang S; Zhang XB; Li WJ; Hao XM; Zhang J
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670
[TBL] [Abstract][Full Text] [Related]
18. QT duration and dispersion in patients with anomalous origins of coronary arteries.
Kargin R; Pala S; Akçakoyun M; Esen O; Demirkiran A; Karapinar H; Rasulzada M; Bitigen A; Emiroglu Y; Ozdemir N
Pacing Clin Electrophysiol; 2009 Sep; 32(9):1163-7. PubMed ID: 19719493
[TBL] [Abstract][Full Text] [Related]
19. Presence of prolonged dispersion of qt intervals in late survivors of childhood anthracycline therapy.
Gupta M; Thaler HT; Friedman D; Steinherz L
Pediatr Hematol Oncol; 2002 Dec; 19(8):533-42. PubMed ID: 12487828
[TBL] [Abstract][Full Text] [Related]
20. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma.
Nousiainen T; Vanninen E; Rantala A; Jantunen E; Hartikainen J
J Intern Med; 1999 Apr; 245(4):359-64. PubMed ID: 10356598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
